TY - JOUR
T1 - Fine tuning of agonistic/antagonistic activity for Vitamin D receptor by 22-alkyl chain length of ligands
T2 - 22S-Hexyl compound unexpectedly restored agonistic activity
AU - Anami, Yasuaki
AU - Sakamaki, Yuta
AU - Itoh, Toshimasa
AU - Inaba, Yuka
AU - Nakabayashi, Makoto
AU - Ikura, Teikichi
AU - Ito, Nobutoshi
AU - Yamamoto, Keiko
N1 - Funding Information:
This work was partially supported by Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science, and Technology, Japan and by a Grant-in-Aid for Scientific Research (no. 26460155) from the Ministry of Education, Culture, Sports, Science, and Technology , Japan. We also thank the MEXT -Supported Program for the Strategic Research Foundation at Private Universities (2013-2017) and the Takeda Science Foundation , Japan, for financial support. Synchrotron-radiation experiments were performed at the Photon Factory (Proposal No. 2013G656) for the VDR–LBD/ 3 complex and Spring-8 (Proposal No. 2008B1424) for the VDR–LBD/ 5 complex, and we are grateful for the assistance provided by the beamline scientists at the Photon Factory and Spring-8.
Publisher Copyright:
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license.
PY - 2015/11/15
Y1 - 2015/11/15
N2 - 1α,25-DihydroxyVitamin D3 exerts its actions by binding to Vitamin D receptor (VDR). We are continuing the study related to the alteration of pocket structure of VDR by 22-alkyl substituent of ligands and the relationships between the alteration and agonistic/antagonistic activity. Previously we reported that compounds 2 (22-H), 3 (22S-Et), and 4 (22S-Bu) are VDR agonist, partial agonist and antagonist, respectively. Here, we describe the synthesis and biological evaluation of 22S-hexyl analog 5 (22S-Hex), which was designed to be a stronger VDR antagonist than 4. Unexpectedly, 5 showed partial agonistic but not antagonistic activity when bound to VDR, indicating that it is not necessarily true that the bulkier the side chain is, the stronger the antagonistic activity will be. X-ray crystallographic analysis of the VDR-ligand-binding domain (VDR-LBD) accommodating compound 5 indicated that the partial agonist activity of 5 is dependent on the mixed population of the agonistic and antagonistic conformations. Binding of compound 5 may not bring the complex into the only antagonistic conformation due to the large conformational change of the VDR-LBD. From this study it was found that fine tuning of agonistic/antagonistic activity for VDR is possible by 22-alkyl chain length of ligands.
AB - 1α,25-DihydroxyVitamin D3 exerts its actions by binding to Vitamin D receptor (VDR). We are continuing the study related to the alteration of pocket structure of VDR by 22-alkyl substituent of ligands and the relationships between the alteration and agonistic/antagonistic activity. Previously we reported that compounds 2 (22-H), 3 (22S-Et), and 4 (22S-Bu) are VDR agonist, partial agonist and antagonist, respectively. Here, we describe the synthesis and biological evaluation of 22S-hexyl analog 5 (22S-Hex), which was designed to be a stronger VDR antagonist than 4. Unexpectedly, 5 showed partial agonistic but not antagonistic activity when bound to VDR, indicating that it is not necessarily true that the bulkier the side chain is, the stronger the antagonistic activity will be. X-ray crystallographic analysis of the VDR-ligand-binding domain (VDR-LBD) accommodating compound 5 indicated that the partial agonist activity of 5 is dependent on the mixed population of the agonistic and antagonistic conformations. Binding of compound 5 may not bring the complex into the only antagonistic conformation due to the large conformational change of the VDR-LBD. From this study it was found that fine tuning of agonistic/antagonistic activity for VDR is possible by 22-alkyl chain length of ligands.
KW - Ligand-binding pocket
KW - Nuclear receptor
KW - Partial agonist
KW - Vitamin D
KW - X-ray crystallographic structure
UR - http://www.scopus.com/inward/record.url?scp=84946208245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946208245&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2015.10.026
DO - 10.1016/j.bmc.2015.10.026
M3 - Article
C2 - 26515040
AN - SCOPUS:84946208245
SN - 0968-0896
VL - 23
SP - 7274
EP - 7281
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 22
ER -